Merz looks to invest in early-stage aesthetics

11 June 2015 - Deborah Wilkes

Merz Pharma plans to invest up to €25 million (US$28 million) of corporate venture capital in the aesthetics market. The privately-held company has also just arranged a syndicated loan of up to €500 million, giving it "the greatest possible freedom going forward".